Pinterest • The world’s catalog of ideas

Explore Oncotype Dx, Treatment Decisions, and more!

Oncotype DX May Help Make Treatment Decisions for Breast Cancer That’s Metastatic at Diagnosis

Using the Oncotype DX breast cancer test to personalize treatment. Not every woman with early-stage breast cancer requires the same treatment. Dr. Marisa Weiss and Dr. Ruth Oratz talk about the Oncotype DX breast cancer test, which is used to tailor treatment and helps women and their doctors determine the best treatment for their cancer type.

Oncotype DX Testing Lets Some Breast Ca Patients Skip Chemo

Oncotype DX Testing Lets Some Breast Cancer Patients Skip Chemo - Low 21-gene score meant 98% disease-free survival with endocrine therapy alone. "This Oncotype genomic assay is already widely used for guiding adjuvant treatment decisions in hormone receptor (HR)-positive breast cancer for which the benefit of chemotherapy is unclear." Read more...

What's Different About Male Breast Cancer?

Risk factors for male breast cancer include genetic variants, obesity and high estrogen levels. Carl uses a genomic test called Oncotype DX to help personalize his breast cancer treatment.

Breast Cancer Gene Test Helps Predict Who Can Skip Chemo

For patients who fell into Oncotype DX's low-risk category, 99 percent didn't develop metastatic breast cancer five years after surgery, even if they didn't have chemotherapy.

Younger patients with breast cancer who received Oncotype DX for breast cancer test had reduced use of chemotheray.

#Lumpectomy plus radiation or #mastectomy for early-stage #breastcancer? Listen to Dr. Marisa Weiss in this podcast to help inform your decision in choosing the best treatment for your early-stage breast cancer. #PassItOn

Oncotype DX Testing Lets Some Breast Ca Patients Skip Chemo

Oncotype DX Testing Lets Some Breast Cancer Patients Skip Chemo - Low 21-gene score meant 98% disease-free survival with endocrine therapy alone. "This Oncotype genomic assay is already widely used for guiding adjuvant treatment decisions in hormone receptor (HR)-positive breast cancer for which the benefit of chemotherapy is unclear." Read more...

Findings from a new study that looked at how well the Oncotype DX breast cancer test would predict recurrence for DCIS Stage 0 breast cancer in the real world were presented at San Antonio.